

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/246,307	02/08/1999	ALAN P. KOZIKOWSKI	9928-0009-99	6016
7	590 04/04/2002			
SCULLY, SCOTT, MURPHY & PRESSER			EXAMINER	
400 GARDEN CITY PLAZA GARDEN CITY,, NY 11530		GUPTA, ANISH		
			ART UNIT	PAPER NUMBER
			1652	

DATE MAILED: 04/04/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/246,307	KOZIKOWSKI ET AL.			
7.4.7.5 c. , 7.10 ii c.;	Examiner	Art Unit			
	Anish Gupta	1653			
The MAILING DATE of this communication appe	ars on the cover sheet with the c	correspondence address			
THE REPLY FILED 7-11-01 FAILS TO PLACE THIS AF Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may <u>only</u> be either: (1 condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applice 1) a timely filed amendment whi	cation. A proper reply to a ch places the application in			
PERIOD FOR RE	PLY [check either a) or b)]				
 a) The period for reply expires 6 mont months from the mailing b) The period for reply expires on: (1) the mailing date of this Advevent, however, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f). 	isory Action, or (2) the date set forth in th an SIX MONTHS from the mailing date o FILED WITHIN TWO MONTHS OF THI	f the final rejection. E FINAL REJECTION. See MPEP			
Extensions of time may be obtained under 37 CFR 1.136(a). The dathave been filed is the date for purposes of determining the period of extens 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three moleaned patent term adjustment. See 37 CFR 1.704(b).	sion and the corresponding amount of the I statutory period for reply originally set in	e fee. The appropriate extension fee under the final Office action; or (2) as set forth in			
1. A Notice of Appeal was filed on Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal.					
2. The proposed amendment(s) will not be entered be	ecause:				
(a) they raise new issues that would require further	er consideration and/or search ((see NOTE below);			
(b) \(\square\) they raise the issue of new matter (see Note b	pelow);				
(c) they are not deemed to place the application i issues for appeal; and/or	in better form for appeal by mat	erially reducing or simplifying the			
(d) they present additional claims without cancel NOTE:	ing a corresponding number of	finally rejected claims.			
3. Applicant's reply has overcome the following reject	tion(s):				
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a s	separate, timely filed amendment			
5. ☑ The a) ☐ affidavit, b) ☐ exhibit, or c) ☑ request fo application in condition for allowance because: See		sidered but does NOT place the			
6. The affidavit or exhibit will NOT be considered becaused by the Examiner in the final rejection.	cause it is not directed SOLELY	to issues which were newly			
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	• • • •	·			
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed: none.					
Claim(s) objected to: 73.					
Claim(s) rejected: <u>12-17,20-28,31,32 and 74-81</u> .					
Claim(s) withdrawn from consideration:					
8. \square The proposed drawing correction filed on is	a) ☐ approved or b) ☐ disapp	proved by the Examiner.			
9. \square Note the attached Information Disclosure Stateme	nt(s)(PTO-1449) Paper No(s).	•			
10. Other:	,	Christopher S. F. LOW SUPERVISORY PATENT EXAMINER SECHNOLOGY CENTER 1600			





Continuation of 5. does NOT place the application in condition for allowance because: of the following reasons: For the 112 First paragraph rejection, Applicants have argued that the specification sets forth variety of in-vitro tests that demonstrate neruprotection against both acute and chronic neurodegenerative disorders. Applicants state make referece to a declaration submitted by Dr. Faden in the parent application 09/022,184 that show that the compounds offered neuroprotection from excitotoxic injury, ischemic injury, traumatic injury, nerotic injury and apoptotic cell death caused by staurosporine. The reliance on the Patel reference is misplaced since number of drugs have been approved prior to priority date of the invention that show reproducible cognition enhancment in patients with alzheimers disease.

Applicants response and the declaration by Dr. Faden filed 7-11-01 has been considered but is not found persuasive.

First, applicants reliance on the in-vitro methodology is not sufficient to overcome the rejection. Again attention is directed to the Patel et al. reference which concludes, even after reviewing various known Alzheimer therapies, that the search for an effective cognition-enhancing therapy has so far proved elusive (see page 90). The art indicates that there is no predictive value associated with in-vitro methodology for the treatment of Alzheimerr's disease. Thus, the rejection is maintained for the reasons set forth in the previous office actions and the reasons set forth above.

Finally, note that the IDS filed along with the response has not been considred since it was filed after the mailing date of the final office action. Note that 1.94(c) requires that the submission be made before the mailing of the final office action. In this case, the IDS was submitted 6months after the mailing of the final action.

